ArticleCase reports in oncology
Immune Checkpoint Inhibitor-Induced Bullous Pemphigoid: Successful Treatment with Dupilumab while Maintaining Immunotherapy.
Article in Case reports in oncology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Immune checkpoint inhibitor-induced bullous pemphigoid: a systematic review of clinical characteristics and outcomes based on case reports.Frontiers in immunology · 2026Pooled it
- Efficacy and Safety of Dupilumab in Immune Checkpoint Inhibitor Induced Bullous Pemphigoid: A Spanish Multicentric Case Series.Acta dermato-venereologica · 2026Observational
- Dupilumab Can Be Effective for Immune-Related Adverse Event Dermatitis: A Case Report and Review of the Literature.Clinical, cosmetic and investigational dermatology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Immune checkpoint inhibitors (ICIs) represent a new class of antitumor agents in oncology. Their use has been associated with a specific safety profile, known as immune-related adverse events (irAEs), with dermatological toxicities being the most frequently encountered. Case Report: We report the case of a bullous pemphigoid (BP) in a metastatic melanoma patient, treated with ipilimumab and nivolumab. This immune-mediated toxicity was controlled by using dupilumab as a steroid-sparing therapy, allowing the reintroduction of immunotherapy without relapse. Conclusion: This case illustrates the complexity of managing some dermatological irAEs and the need for better treatment strategies. Dupilumab is a promising agent for cutaneous irAEs, including ICI-BP. To our knowledge, our case is the first one in which a rechallenge with an ICI was attempted after a dupilumab treatment for an ICI-BP.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.